Cohance Lifesciences Limited (NSE:COHANCE)

Cohance Lifesciences Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 4, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	207,562	293,004	172,366	120,256	157,436	126,468
Market Cap Growth	-36.35%	69.99%	43.33%	-23.61%	24.49%	394.20%
Enterprise Value	209,433	287,341	165,176	117,048	156,449	127,128
Last Close Price	542.55	1151.00	677.10	472.40	608.53	484.99
PE Ratio	78.87	109.38	57.40	29.24	34.69	34.90
Forward PE	40.16	63.44	44.40	26.23	30.48	29.75
PS Ratio	17.15	24.47	16.40	8.97	11.93	12.53
PB Ratio	5.29	15.92	8.40	6.93	10.31	10.71
P/TBV Ratio	8.53	29.97	8.67	7.19	10.32	10.73
P/FCF Ratio	151.96	221.22	51.78	70.21	61.79	46.55
P/OCF Ratio	99.93	101.68	44.80	26.30	47.71	33.06
PEG Ratio	2.87	3.42	3.42	3.42	-	-
EV/Sales Ratio	17.30	23.99	15.71	8.73	11.85	12.59
EV/EBITDA Ratio	67.54	70.85	40.39	20.44	27.00	28.85
EV/EBIT Ratio	99.50	87.58	46.61	22.25	28.89	31.02
EV/FCF Ratio	153.33	216.94	49.62	68.34	61.40	46.79
Debt / Equity Ratio	0.12	0.15	0.03	0.04	0.06	0.12
Debt / EBITDA Ratio	1.45	0.69	0.16	0.12	0.17	0.32
Debt / FCF Ratio	3.30	2.11	0.20	0.41	0.38	0.53
Asset Turnover	0.30	0.45	0.50	0.71	0.80	0.76
Inventory Turnover	0.84	1.85	1.32	1.87	2.24	2.19
Quick Ratio	1.59	1.78	8.61	4.17	3.85	1.56
Current Ratio	2.92	2.43	10.68	6.37	5.36	2.57
Return on Equity (ROE)	5.51%	13.61%	15.86%	25.21%	33.52%	35.78%
Return on Assets (ROA)	3.26%	7.76%	10.50%	17.33%	20.49%	19.35%
Return on Capital (ROIC)	4.08%	9.68%	11.30%	19.18%	22.96%	21.76%
Return on Capital Employed (ROCE)	4.30%	12.30%	16.60%	29.10%	33.40%	32.70%
Earnings Yield	0.85%	0.91%	1.74%	3.42%	2.88%	2.86%
FCF Yield	0.66%	0.45%	1.93%	1.42%	1.62%	2.15%
Dividend Yield	-	-	-	-	0.33%	0.41%
Payout Ratio	-	-	-	49.52%	11.22%	7.03%
Buyback Yield / Dilution	-0.56%	-0.49%	-	-	-	0.00%
Total Shareholder Return	-0.56%	-0.49%	-	-	0.33%	0.41%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.